Matthew Sericati, MD
Gastroenterology · Boise, IDNPI 1194871871
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $92,969 of the $110,780 with a category attached, or 83.9%. AbbVie accounts for 98.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $42,246 and has fallen 97.7% since, to $959 in 2025. Among gastroenterology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 312 payments — averaging $355.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$109K
- Takeda Pharmaceuticals U.S.A., Inc.$284
- QOL Medical, LLC$255
- Bristol Myers Squibb$215
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$176
- Enterra Medical, Inc.$156
- plus $749 from 19 others
What the payments were for
- Speaking & faculty fees$92,96984%
- Travel & lodging$9,4599%
- Food & beverage$8,2967%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 249 | $108,944 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $284 |
| QOL Medical, LLC | 5 | $255 |
| Bristol Myers Squibb | 3 | $215 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $176 |
| Enterra Medical, Inc. | 1 | $156 |
| Phathom Pharmaceuticals, Inc. | 2 | $117 |
| Pfizer | 6 | $96 |
| Ambu Inc. | 1 | $90 |
| Merck | 4 | $66 |
| Madrigal Pharmaceuticals | 1 | $48 |
| Gilead | 2 | $43 |
| Braintree Laboratories, Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $35 |
| Boston Scientific | 1 | $34 |
| Amgen | 1 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $13 |
| Conmed Corporation | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$110,780 in reported general payments places this provider in the 95th percentile of 70 gastroenterology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 36 | $22,908 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 270 | $17,486 |
| Mesalamine | 18 | $4,400 |
| Opium Tincture | 11 | $2,230 |
| Omeprazole | 168 | $2,198 |
| Promethazine Hcl | 48 | $2,085 |
| Colestipol Hcl | 32 | $1,937 |
| Ondansetron OdtOndansetron | 347 | $1,452 |
| Sucralfate | 44 | $1,052 |
| Famotidine | 40 | $719 |
| Pantoprazole Sodium | 66 | $708 |
| Lactated RingersRinger's Solution,lactated | 18 | $685 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 30 | $514 |
| FamotidineFamotidine/Pf | 35 | $503 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $108,944 | $22,90836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 70 gastroenterology providers in Idaho.
Other gastroenterology in Boise
- Ashley EvansBoise$69K
- Bryan BrimhallBoise$10K
- Lauren SheaBoise$6K
- Stephen SchutzBoise$5K
- Mark MalloryBoise$4K
- Joseph CookBoise$4K
- Jeffrey BankBoise$4K
- Rebecca OsterkampBoise$3K
- Victor ChenBoise$3K
- Edward KrajicekBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.